Renal dysplasia/hypoplasia, Williams Syndrome phenotype and non-Hodgkin lymphoma in the same patient: only a coincidence?


Congenital renal anomalies, Williams Syndrome and non-Hodgkin lymphoma all occur separately at low incidence, so their simultaneous presence in the same patient is exceptional. We present a young patient manifesting all three conditions. This child is a boy with a Williams Syndrome phenotype who was diagnosed with severe chronic kidney disease secondary to bilateral renal dysplasia/hypoplasia. Due to his small size, he received treatment with growth hormone. He progressed to end stage kidney disease and, after 8 months, a renal transplant was performed. A number of suspicious abdominal adenopathies were removed during the surgery and, thereafter, immunosupressive treatment with prednisone, azathioprine and cyclosporine was initiated. Examination of the biopsy tissue confirmed the presence of a T-cell lymphoblastic lymphoma. Appropriate chemotherapy was given, and the immunosupressive regimen was eventually reduced to prednisone alone. Now, 8 years since the initial diagnosis of T-cell lymphoblastic lymphoma and 6 years after the completion of the chemotherapy, the patient is still in complete remission with a functional donor kidney. We discuss some possible explanations of this association. Chemotherapy has not appeared to have affected the viability of the grafted kidney and, in fact, it may even have induced immunotolerance.

This is a preview of subscription content, access via your institution.


  1. 1.

    Pope JC 4th, Brock JW 3rd, Adams MC, Stephens FD, Ichikawa I (1999) How the begin and how the end: classic and new theories for the development and deterioration of congenital anomalies of the kidney and urinary tract, CAKUT. J Am Soc Nephrol 10:2018–2028

    PubMed  Google Scholar 

  2. 2.

    Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A (2003) Chronic renal insufficiency in children: the 2001 Annual Report of NAPRTCS. Pediatr Nephrol 18:796–804

    Article  Google Scholar 

  3. 3.

    Committee on Genetics (2001) American Academy of Pediatrics: health care supervision for children with Williams Syndrome. Pediatrics 107:1192–1204

    Google Scholar 

  4. 4.

    Ewart AK, Morris CA, Atkinson D, Jim W, Sternes K, Spallone P, Stock AD, Leppert M, Keating MT (1993) Hemizygosity at the elastin locus in a developmental disorder, Williams Syndrome. Nat Genet 5:11–16

    CAS  Article  Google Scholar 

  5. 5.

    Nathan DG, Orkin SH, Look T (2003) Nathan & Oski’s hematology of infancy and childhood, 6th edn. Saunders, Philadelphia

  6. 6.

    Sanna-Cherchi S, Caridi G, Weng PL, Scolari F, Perfumo F, Charavi AG, Ghiggeri GM (2007) Genetic approaches to human renal agenesis/hypoplasia and dysplasia. Pediatr Nephrol 22:1675–1684

    Article  Google Scholar 

  7. 7.

    Schedl A (2007) Renal abnormalities and their developmental origin. Nat Rev Genet 8:791–802

    CAS  Article  Google Scholar 

  8. 8.

    Tassabehji M (2003) Williams–Beuren syndrome: a challenge for genotype–phenotype correlations. Hum Mol Genet 12:R229–R237

    CAS  Article  Google Scholar 

  9. 9.

    Guo XL, Pan L, Zhang XJ, Suo XH, Niu ZY, Zhang JY, Wang F, Dong ZR, Da W, Ohno R (2007) Expression and mutation analysis of genes that encodes the Myc antagonist Mad1, Mxi1 and Rox in acute leukaemia. Leuk Lymphoma 48:1200–1207

    CAS  Article  Google Scholar 

  10. 10.

    Dean HJ, Kellet JG, Bala RM, Guyda HJ, Bhaumick B, Posner BI, Friesen HG (1982) The effect of growth hormone treatment on somatomedin levels in growth hormone deficient children. J Clin Endocrinol Metab 55:1167–1173

    CAS  Article  Google Scholar 

  11. 11.

    Ghigo E, Aimaretti G, Maccario M, Fanciulli G, Arvat E, Minuto F, Giordano G, Delitala G, Camanni F (1999) Dose-response study of GF effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am J Physiol 276:E1009–E1013

    CAS  PubMed  Google Scholar 

  12. 12.

    Cohen P, Clemmons DR, Rosenfeld RG (2000) Does the GH-IGF axis play a role in cancer pathogenenesis? Growth Horm IGF Res 10:297–305

    CAS  Article  Google Scholar 

  13. 13.

    Swerdlow AJ, Higgins CD, Adlard P, Preece MA (2002) Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 360:273–277

    CAS  Article  Google Scholar 

  14. 14.

    Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wüster C (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 50:703–713

    CAS  Article  Google Scholar 

  15. 15.

    El Cheik J, de Colella JM, Vacher-Copponat H, Moal V, Costello RT (2006) Non-Hodgkin’s lymphoma after kidney transplantation: a single institution study. Leuk Res 30:118–119

    Article  Google Scholar 

  16. 16.

    Rubio-Viqueira B, Hidalgo M (2006) Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7:501–512

    CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Adela Urisarri-Ruiz de Cortázar.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Urisarri-Ruiz de Cortázar, A., Calvo, M.G., Donsión, M.V. et al. Renal dysplasia/hypoplasia, Williams Syndrome phenotype and non-Hodgkin lymphoma in the same patient: only a coincidence?. Pediatr Nephrol 24, 1081–1084 (2009).

Download citation


  • Chemotherapy
  • Growth hormone
  • Immunosuppression
  • Neoplasia
  • Renal transplant
  • Williams Syndrome